pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Bispecific Antibody · news · pharmadog
← back to Bispecific Antibody
News · Bispecific Antibody
285
stories
Aug 11, 26
Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
fiercebiotech
Aug 11, 26
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
fiercebiotech
Aug 10, 26
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
fiercebiotech
Aug 10, 26
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
Aug 6, 26
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
Aug 5, 26
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
Aug 4, 26
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
Aug 4, 26
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
biospace
Aug 4, 26
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
Aug 3, 26
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
Aug 3, 26
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
Aug 3, 26
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
Jul 29, 26
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
biospace
Jul 29, 26
Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor
endpoints
Jul 29, 26
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 29, 26
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
Jul 27, 26
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 24, 26
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 17, 26
Jasper gets a lifeline in merger with immune drugmaker Kira
biopharma dive
Jul 6, 26
Cancer, immune drugmakers dominate VC funding so far in 2026
biopharma dive
Jul 1, 26
STAT+: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenes
stat
Jun 30, 26
AbbVie and Genmab's latest win brings Epkinly closer to label expansion
endpoints
Jun 30, 26
These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
biopharma dive
Jun 30, 26
STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk
stat
Jun 30, 26
STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
stat
← prev
page 6 of 10
next →